nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.08.2013 | Review

Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies

verfasst von: Linjuan Xu, Jing Cai, Qiang Yang, Hui Ding, Liying Wu, Tao Li, Zehua Wang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

Abnormal expression of several biomarkers might predict disease prognosis and response to chemotherapy in patients with epithelial ovarian cancer (EOC). However, the published data are inconsistent.

Methods

Eligible studies that investigated the association between survival or response to platinum-based chemotherapy in EOC and the expression status of Bcl-2, EGFR, GST, LRP, p16, p21, P-gp and TNF-α were identified by an electronic search of PubMed and Embase. The measures of interest were hazard ratio (HR) for survival or risk ratio for chemotherapy response. A meta-analysis was performed using the fixed-effect or random-effect models.

Results

The number of eligible studies analyzed was 27 for Bcl-2, 22 for EGFR, 29 for GST, 12 for LRP, 16 for p16, 22 for p21, 27 for P-gp and three for TNF-α. A meta-analysis showed that high EGFR and P-gp expression was associated with poor overall survival (OS) (pooled adjusted HR = 1.826 and HR = 1.822). Only high GST expression was associated with improved OS (HR = 0.780). Furthermore, high p16 and P-gp expression was associated with poor progression-free survival (PFS) (HR = 1.550 and HR = 2.136). High GST expression was associated with improved PFS (HR = 0.689). Among these factors, only LRP, P-gp and TNF-α were associated with response to platinum-based chemotherapy.

Conclusions

The markers we analyzed are unlikely to be useful as predictors of prognosis and response to platinum-based chemotherapy in EOC patients in clinical practice.

Anttila MA, Kosma VM, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjänen K (1999) p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 79(11–12):1870–1878PubMedCrossRef

Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemse PH, van der Zee AG et al (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5(10):2798–2805PubMed

Asschert JG, Vellenga E, Hollema H, van der Zee AG, de Vries EG (1997) Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas. Eur J Cancer 33(13):2246–2251PubMedCrossRef

Avraam K, Pavlakis K, Papadimitriou C, Vrekoussis T, Panoskaltsis T, Messini I, Patsouris E (2011) The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer. Eur J Gynaecol Oncol 32(5):516–520PubMed

Baekelandt M, Kristensen GB, Nesland JM, Tropé CG, Holm R (1999a) Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol 17(7):2061PubMed

Baekelandt M, Kristensen GB, Tropé CG, Nesland JM, Holm R (1999b) Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res 19(5C):4469–4474PubMed

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999c) Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res 5(10):2848–2853PubMed

Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000) P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 20(2B):1061–1067PubMed

Bali A, O’Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM (2004) Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10(15):5168–5177PubMedCrossRef

Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A et al (2008) Correlation of NK T-like CD3 + CD56 + cells and CD4 + CD25 + (hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 108(2):421–427PubMedCrossRef

Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H (2006) Glutathione s-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 100(2):330–337PubMedCrossRef

Bilyk OO, Pande NT, Buchynska LG (2011) Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas. Exp Oncol 33(3):150–156PubMed

Blegen H, Einhorn N, Sjövall K, Roschke A, Ghadimi BM, McShane LM, Nilsson B, Shah K, Ried T, Auer G (2000) Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int J Gynecol Cancer 10(6):477–487PubMedCrossRef

Brinkhuis M, Izquierdo MA, Baak JP, van Diest PJ, Kenemans P, Scheffer GL, Scheper RJ (2002) Expression of multidrug resistance-associated markers, their relation to quantitative pathologic tumour characteristics and prognosis in advanced ovarian cancer. Anal Cell Pathol 24(1):17–23PubMed

Brustmann H (2008) Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol 27(3):380–389PubMedCrossRef

Camilleri-Broët S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J, Pujade-Lauraine E, GINECO group (2004) HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 15(1):104–112PubMedCrossRef

Chang F, Lacey MR, Bouljihad M, Höner Zu, Bentrup K, Fortgang IS (2012) Tumor necrosis factor receptor 1 functions as a tumor suppressor. Am J Physiol Gastrointest Liver Physiol 302(2):G195–G206PubMedCrossRef

Chen AP, Zhang J, Liu H, Zhao SP, Dai SZ, Sun XL (2009) Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma. Zhonghua Zhong Liu Za Zhi 31(1):48–52PubMed

Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N (1997) Glutathione s-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 79(3):521–527PubMedCrossRef

Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D’Incalci M (1997) Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 65(1):130–137PubMedCrossRef

Costa MJ, Hansen CL, Walls JE, Scudder SA (1999) Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy. Hum Pathol 30(6):640–647PubMedCrossRef

Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E (2000) Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne’s syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues. Biochem Pharmacol 60(11):1611–1619PubMedCrossRef

Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M, Goldberg I, Kopolovic J, Berner A (2000) E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol 79(3):362–371PubMedCrossRef

Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006) Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 12(3 Pt 1):791–799PubMedCrossRef

De Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99(2):341–349PubMedCrossRef

De Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 101(1):149–159PubMedCrossRef

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRef

Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, Löhrs U (1996) bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105(3):341–349PubMed

Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, Hurst T, Khoo SK, Parsons PG (1997) Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 74(1):57–63PubMedCrossRef

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRef

Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broët P, Marmey B, Chauvenet L, Audouin J, Pujade-Lauraine E, Camilleri-Broët S, GINECO Group (2004) Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 91(3):470–475PubMedCrossRef

Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B (2009) Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol 28(3):211–221PubMedCrossRef

Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A (2004) Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 95(2):377–383PubMedCrossRef

Ferrandina G, Scambia G, Damia G, Tagliabue G, Fagotti A, Panici PB, Mangioni C, Mancuso S, D’Incalci M (1997) Glutathione s-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann Oncol 8(4):343–350PubMedCrossRef

Ferrandina G, Stoler A, Fagotti A, Fanfani F, Sacco R, De Pasqua A, Mancuso S, Scambia G (2000) p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol 17(6):1231–1235PubMed

Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, Nicotra MR, Natali PG, Zakut VH, Scambia G (2002) Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 85(2):305–310PubMedCrossRef

Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R (1997) EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17(1B):613–619PubMed

Fujiki H, Suganuma M (2011) Tumor promoters–microcystin-LR, nodularin and TNF-α and human cancer development. Anticancer Agents Med Chem 11(1):4–18PubMedCrossRef

Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, Wada H, Buzard GS, Matsuzaki N, Wakasa K, Murata Y (1997) Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 74(2):148–155PubMedCrossRef

Galani E, Sgouros J, Petropoulou C, Janinis J, Aravantinos G, Dionysiou-Asteriou D, Skarlos D, Gonos E (2002) Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Anticancer Res 22(4):2275–2280PubMed

Germain I, Têtu B, Brisson J, Mondor M, Cherian MG (1996) Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int J Gynecol Pathol 15(1):54–62PubMedCrossRef

Ghazal-Aswad S, Hogarth L, Hall AG, George M, Sinha DP, Lind M, Calvert AH, Sunter JP, Newell DR (1996) The relationship between tumour glutathione concentration, glutathione s-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Br J Cancer 74(3):468–473PubMedCrossRef

Giordano G, Azzoni C, D’Adda T, Rocco A, Gnetti L, Froio E, Merisio C, Melpignano M (2008) Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Pathol Res Pract 204(3):163–174PubMedCrossRef

Goff BA, Ries JA, Els LP, Coltrera MD, Gown AM (1998) Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 70(3):378–385PubMedCrossRef

Goff BA, Paley PJ, Greer BE, Gown AM (2001) Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol Oncol 81(1):18–24PubMedCrossRef

Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE (2005) The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 11(10):3733–3742PubMedCrossRef

Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y (2006) Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol Rep 15(5):1265–1271PubMed

Goto T, Takano M, Hirata J, Kohno T, Ohtsuka S, Fujiwara K, Tsuda H (2009) p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer. Int J Cancer 125(2):339–344PubMedCrossRef

Green JA, Robertson LJ, Clark AH (1993) Glutathione s-transferase expression in benign and malignant ovarian tumours. Br J Cancer 68(2):235–239PubMedCrossRef

Green JA, Berns EM, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RH, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC et al (2006) Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur J Cancer 42(15):2539–2548PubMedCrossRef

Hamada S, Kamada M, Furumoto H, Hirao T, Aono T (1994) Expression of glutathione s-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 52(3):313–319PubMedCrossRef

Hattori M, Sakamoto H, Yamamoto T (2001) DNA demethylase expression correlates with lung resistance protein expression in common epithelial ovarian cancers. J Int Med Res 29(3):204–213PubMedCrossRef

Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427–437PubMedCrossRef

Hengstler JG, Pilch H, Schmidt M, Dahlenburg H, Sagemüller J, Schiffer I, Oesch F, Knapstein PG, Kaina B, Tanner B (2001) Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer 95(2):121–127PubMedCrossRef

Henriksen R, Wilander E, Oberg K (1995) Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 72(5):1324–1329PubMedCrossRef

Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56(9):2178–2184PubMed

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef

Hirazono K, Shinozuka T, Kuroshima Y, Itoh H, Kawai K (1995) Immunohistochemical expression of glutathione s-transferase pi (GST-pi) and chemotherapy response in malignant ovarian tumors. J Obstet Gynaecol (Tokyo 1995) 21(3):305–312CrossRef

Hirte H, Oza A, Swenerton K, Ellard SL, Grimshaw R, Fisher B, Tsao M, Seymour L (2010) A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149. Gynecol Oncol 118(3):308–312PubMedCrossRef

Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Høgdall CK (2010) Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study. APMIS 118(8):557–564PubMedCrossRef

Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB (1992) Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84(19):1486–1491PubMedCrossRef

Howells RE, Redman CW, Dhar KK, Sarhanis P, Musgrove C, Jones PW, Alldersea J, Fryer AA, Hoban PR, Strange RC (1998) Association of glutathione s-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res 4(10):2439–2445PubMed

Howells RE, Holland T, Dhar KK, Redman CW, Hand P, Hoban PR, Jones PW, Fryer AA, Strange RC (2001) Glutathione s-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int J Gynecol Cancer 11(2):107–112PubMedCrossRef

Howells RE, Dhar KK, Hoban PR, Jones PW, Fryer AA, Redman CW, Strange RC (2004) Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer. Int J Gynecol Cancer 14(2):242–250PubMedCrossRef

Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, Kohno K (2004) Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 93(2):287–291PubMedCrossRef

Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H, Shimizu M, Minakami H, Sakuragi N (2003) Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 13(6):776–784PubMedCrossRef

Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Beliën JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJ, de Vries EG et al (1995) Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87(16):1230–1237PubMedCrossRef

Jancárková N, Krkavcová M, Janashia M, Freitag P (2006) Prognostic factors of ovarian cancer. Ceska Gynekol 71(3):252–259PubMed

Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Tropé C (2005) Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 15(6):1014–1022PubMedCrossRef

Kassim SK, Ali HS, Sallam MM, Fayed ST, Seada LS, abd-Elkawy E, Seada MA, Khalifa A (1999) Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin Biochem 32(5):333–338PubMedCrossRef

Katsaros D, Cho W, Singal R, Fracchioli S, Rigault De La Longrais IA, Arisio R, Massobrio M, Smith M, Zheng W, Glass J, Yu H (2004) Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94(3):685–692PubMedCrossRef

Kavallaris M, Leary JA, Barrett JA, Friedlander ML (1996) MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 102(1–2):7–16PubMedCrossRef

Khalifa MA, Abdoh AA, Mannel RS, Walker JL, Angros LH, Min KW (1997) P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma. Int J Gynecol Pathol 16(1):69–75PubMedCrossRef

Khalifeh I, Munkarah AR, Schimp V, Morris R, Lawrence WD, Ali-Fehmi R (2005) The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. Int J Gynecol Pathol 24(3):228–234PubMedCrossRef

Khouja MH, Baekelandt M, Nesland JM, Holm R (2007) The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 26(4):418–425PubMedCrossRef

Kim KK, Shim JC, Kim JR (2003) Overexpression of p21, cyclin E and decreased expression of p27 in DMBA (7, 12-dimethylbenzanthracene)-induced rat ovarian carcinogenesis. Pathol Int 53(5):291–296PubMedCrossRef

Kolwijck E, Zusterzeel PL, Roelofs HM, Hendriks JC, Peters WH, Massuger LF (2009) GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer Epidemiol Biomarkers Prev 18(8):2176–2181PubMedCrossRef

Kommoss S, du Bois A, Ridder R, Trunk MJ, Schmidt D, Pfisterer J, Kommoss F, AGO-OVAR (2007) Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 96(2):306–313PubMedCrossRef

Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS et al (2011) Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res 17(6):1591–1602PubMedCrossRef

Kudoh K, Ichikawa Y, Yoshida S, Hirai M, Kikuchi Y, Nagata I, Miwa M, Uchida K (2002) Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer 99(4):579–582PubMedCrossRef

Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T, Yamamoto K (1999) The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5(12):4152–4157PubMed

Lallas TA, McClain SK, Shahin MS, Buller RE (2000) The glutathione s-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomarkers Prev 9(6):587–590PubMed

Lamerz R (1999) Role of tumour markers, cytogenetics. Ann Oncol 10(Suppl 4):145–149PubMedCrossRef

Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R (2006) Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) 84(8):671–681CrossRef

Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH, An HJ (2011) Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol 30(3):205–217PubMedCrossRef

Leng J, Lang J, Shen K, Guo L (1997) Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin Med Sci J 12(2):67–70PubMed

Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP (2000) Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clin Cancer Res 6(8):3260–3270PubMed

Lohmann CM, League AA, Clark WS, Lawson D, DeRose PB, Cohen C (2000) Bcl-2: bax and bcl-2: Bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: correlation with prognosis. Cytometry 42(1):61–66PubMedCrossRef

Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H (2007) Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncol Res 16(8):395–403PubMed

Lu D, Shi HC, Wang ZX, Gu XW, Zeng YJ (2011) Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma. Br J Biomed Sci 68(2):69–74PubMed

Malamou-Mitsi V, Crikoni O, Timotheadou E, Aravantinos G, Vrettou E, Agnantis N, Fountzilas G (2007) Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res 27(2):1157–1165PubMed

Mandai M, Konishi I, Koshiyama M, Mori T, Arao S, Tashiro H, Okamura H, Nomura H, Hiai H, Fukumoto M (1994) Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res 54(7):1825–1830PubMed

Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, Ishii K, Nagata I (1999) Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 35(8):1214–1219PubMedCrossRef

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed

Materna V, Pleger J, Hoffmann U, Lage H (2004) RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94(1):152–160PubMedCrossRef

Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M, Lage H (2007) Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep 17(3):505–516PubMed

Matsumoto T, Hayase R, Kodama J, Kamimura S, Yoshinouchi M, Kudo T (1997) Immunohistochemical analysis of glutathione s-transferase π expression in ovarian tumors. Eur J Obstet Gynecol Reprod Biol 73(2):171–176PubMedCrossRef

Mayr D, Pannekamp U, Baretton GB, Gropp M, Meier W, Flens MJ, Scheper R, Diebold J (2000) Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 196(7):469–475PubMedCrossRef

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1):1–6PubMedCrossRef

Meijer GA, Schroeijers AB, Flens MJ, Meuwissen SG, van der Valk P, Baak JP, Scheper RJ (1999) Increased expression of multidrug resistance related proteins P-gp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol 52(6):450–454PubMedCrossRef

Milde-Langosch K, Hagen M, Bamberger AM, Löning T (2003) Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 22(2):168–174PubMedCrossRef

Murphy D, McGown AT, Hall A, Cattan A, Crowther D, Fox BW (1992) Glutathione s-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br J Cancer 66(5):937–942PubMedCrossRef

Muso H (1998) Long-term prognostic factors for chemotherapy of ovarian cancer. Osaka City Med J 44(2):155–171PubMed

Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM (2007) The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 43(2):283–290PubMedCrossRef

Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, Takebayashi Y (2002) Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer 101(5):488–495PubMedCrossRef

Nardone G, Rocco A, Vaira D, Staibano S, Budillon A, Tatangelo F, Sciulli MG, Perna F, Salvatore G, Di Benedetto M, De Rosa G, Patrignani P (2004) Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. J Pathol 202(3):305–312PubMedCrossRef

Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 14(6):1086–1096PubMedCrossRef

Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, Sehouli J, Braicu EI, Budczies J, Dietel M, Denkert C (2011) An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer 11:294PubMedCrossRef

Obata H, Yahata T, Quan J, Sekine M, Tanaka K (2006) Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res 26(3B):2227–2232PubMed

Ochiai K (2006) Prognostic factors of ovarian cancer. Gan To Kagaku Ryoho 33(13):2014–2019PubMed

Oda Y, Ohishi Y, Basaki Y, Kobayashi H, Hirakawa T, Wake N, Ono M, Nishio K, Kuwano M, Tsuneyoshi M (2007) Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expressionv. Cancer Sci 98(7):1020–1026PubMedCrossRef

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200PubMedCrossRef

Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRef

Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93(1):98–106PubMedCrossRef

Petty R, Evans A, Duncan I, Kurbacher C, Cree I (1998) Drug resistance in ovarian cancer - the role of p53. Pathol Oncol Res 4(2):97–102PubMedCrossRef

Plisiecka-Hałasa J, Karpińska G, Szymańska T, Ziółkowska I, Madry R, Timorek A, Debniak J, Ułańska M, Jedryka M, Chudecka-Głaz A, Klimek M, Rembiszewska A et al (2003) P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 14(7):1078–1085PubMedCrossRef

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387):100–103PubMedCrossRef

Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, Dimopoulos AM, Michalas S (2004) The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur J Gynaecol Oncol 25(2):225–229PubMed

Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA (2005) Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 11(24 Pt 1):8637–8643PubMedCrossRef

Raspollini MR, Pinzani P, Pazzagli M, Baroni G, Taddei A, Amunni G, Villanucci A, Taddei GL (2002) Multidrug resistance in ovarian cancer: comparing an immunocytochemical study and ATP-tumor chemosensitivity assay. J Chemother 14(5):518–525PubMed

Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL (2003) Prognostic value of P-glycoprotein and proliferative index in advanced low grade serous ovarian carcinomas. J Chemother 15(4):380–386PubMed

Raspollini MR, Amunni G, Villanucci A, Boddi V, Taddei GL (2005) Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 15(2):255–260PubMedCrossRef

Raspollini MR, Amunni G, Villanucci A, Castiglione F, Degl’Innocenti DR, Baroni G, Paglierani M, Taddei GL (2006) HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl Immunohistochem Mol Morphol 14(2):181–186PubMedCrossRef

Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P et al (2011) Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene 30(38):4038–4049PubMedCrossRef

Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE (2003) p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res 9(3):1028–1032PubMed

Sagarra RA, Andrade LA, Martinez EZ, Pinto GA, Syrjänen KJ, Derchain SF (2002) P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer 12(6):720–727PubMedCrossRef

Saip P, Tuzlali S, Demir K, Sakar B, Yavuz E, Berkman S, Bengisu E, Topuz E (2005) Value of glutathion-S transferase pi as a prognostic factor in epithelial ovarian carcinoma. Eur J Gynaecol Oncol 26(1):90–94PubMed

Scambia G, Catozzi L, Panici PB, Ferrandina G, Coronetta F, Barozzi R, Baiocchi G, Uccelli L, Piffanelli A, Mancuso S (1993) Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor. Am J Obstet Gynecol 168(1 Pt 1):71–78PubMedCrossRef

Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A, Mancuso S (1995) Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72(2):361–366PubMedCrossRef

Scambia G, Masciullo V, Benedetti Panici P, Marone M, Ferrandina G, Todaro N, Bellacosa A, Jain SK, Neri G, Piffanelli A, Mancuso S (1997) Prognostic significance of ras/p21 alterations in human ovarian cancer. Br J Cancer 75(10):1547–1553PubMedCrossRef

Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11(15):5539–5548PubMedCrossRef

Schmider A, Gee C, Friedmann W, Lukas JJ, Press MF, Lichtenegger W, Reles A (2000) p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol 77(2):237–242PubMedCrossRef

Schneider J, Jimenez E, Marenbach K, Marx D, Meden H (1998) Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res 18(4C):2967–2971PubMed

Schuyer M, van der Burg ME, Henzen-Logmans SC, Fieret JH, Klijn JG, Look MP, Foekens JA, Stoter G, Berns EM (2001) Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85(9):1359–1367PubMedCrossRef

Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236PubMedCrossRef

Silvestrini R, Daidone MG, Veneroni S, Benini E, Scarfone G, Zanaboni F, Villa A, Presti M, Danese S, Bolis G (1998) The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 82(1):159–167PubMedCrossRef

Skirnisdóttir I, Sorbe B, Seidal T (2001a) P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int J Gynecol Cancer 11(2):147–158PubMedCrossRef

Skirnisdóttir I, Sorbe B, Seidal T (2001b) The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11(2):119–129PubMedCrossRef

Skirnisdóttir I, Seidal T, Gerdin E, Sorbe B (2002) The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 12(3):265–276PubMedCrossRef

Skírnisdóttir I, Seidal T, Sorbe B (2004) A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer 14(2):259–270PubMedCrossRef

Soh Y, Goto S, Kitajima M, Moriyama S, Kotera K, Nakayama T, Nakajima H, Kondo T, Ishimaru T (2005) Nuclear localisation of glutathione s-transferase pi is an evaluation factor for drug resistance in gynaecological cancers. Clin Oncol (R Coll Radiol) 17(4):264–270CrossRef

Sterne JAC, Egger M, Moher D (2008) Addressing reporting biases. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester, pp 297–334CrossRef

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012PubMedCrossRef

Sui L, Dong Y, Ohno M, Goto M, Inohara T, Sugimoto K, Tai Y, Hando T, Tokuda M (2000) Inverse expression of Cdk4 and p16 in epithelial ovarian tumors. Gynecol Oncol 79(2):230–237PubMedCrossRef

Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Lage H, Zabel M (2005) Augmented expression of metallothionein and glutathione s-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 447(3):626–633PubMedCrossRef

Surowiak P, Materna V, Denkert C, Kaplenko I, Spaczyński M, Dietel M, Zabel M, Lage H (2006) Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett 235(2):272–280PubMedCrossRef

Surowiak P, Materna V, Maciejczyk A, Pudelko M, Suchocki S, Kedzia W, Nowak-Markwitz E, Dumanska M, Spaczynski M, Zabel M, Dietel M, Lage H (2008) Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol Histopathol 23(5):531–538PubMed

Tachibana M, Watanabe J, Matsushima Y, Nishida K, Kobayashi Y, Fujimura M, Shiromizu K (2003) Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: a multivariate analysis of expression of p53, retinoblastoma, and related proteins. Int J Gynecol Cancer 13(5):598–606PubMedCrossRef

Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S, Yamashita Y, Kanemura M, Ueda M, Sugita M, Franklin WA, Ohmichi M (2011) Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 11(1):50–57PubMedCrossRef

Van der Zee AG, van Ommen B, Meijer C, Hollema H, van Bladeren PJ, de Vries EG (1992) Glutathione s-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer 66(5):930–936PubMedCrossRef

Van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG, de Vries EG (1995) Value of P-glycoprotein, glutathione s-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13(1):70–78PubMed

Vassilopoulos I, Korkolopoulou P, Konstantinidou AE, Patsouris E, Eftichiadis C, Thymara I, Perdiki M, Pavlakis K, Agapitos E, Davaris PS (2003) Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas. Histol Histopathol 18(3):761–770PubMed

Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R (1994) Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 30A(7):1002–1007PubMedCrossRef

Viale G, Maisonneuve P, Bonoldi E, Di Bacco A, Bevilacqua P, Panizzoni GA, Radaelli U, Gasparini G (1997) The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. Ann Oncol 8(5):469–476PubMedCrossRef

Wang J, Zhou JY, Zhang L, Wu GS (2009) Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 8(19):3191–3198PubMedCrossRef

Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D, Yu H (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107(2):299–308PubMedCrossRef

Wrigley EC, McGown AT, Buckley H, Hall A, Crowther D (1996) Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome. Br J Cancer 73(6):763–769PubMedCrossRef

Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, Huo LF, Miller S, Hung MC (2009) Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 48(7):610–617PubMedCrossRef

Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, Li K, Fang Y, Weng D, Weng Y, Liao S, Han Z et al (2011) Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer 11:399PubMedCrossRef

Yaginuma Y, Hayashi H, Kawai K, Kurakane T, Saitoh Y, Kitamura S, Sengoku K, Ishikawa M (1997) Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines. Exp Cell Res 233(2):233–239PubMedCrossRef

Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB (2006) Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 100(1):152–159PubMedCrossRef

Yamamoto S, Tsuda H, Kita T, Maekawa K, Fujii K, Kudoh K, Furuya K, Tamai S, Inazawa J, Matsubara O (2007) Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma. Virchows Arch 451(1):27–35PubMedCrossRef

Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y (1999) Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25(6):387–394PubMedCrossRef

Titel: Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies
verfasst von: Linjuan Xu
Jing Cai
Qiang Yang
Hui Ding
Liying Wu
Tao Li
Zehua Wang
Publikationsdatum: 01.08.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1435-z

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies

Abstract

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2013

Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival

Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor

High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma

Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy

EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients

The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS)

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie